BACKGROUND: Many therapeutic options are currently available for facial skin rejuvenation, but little evidence exists about the efficacy of combining such procedures. OBJECTIVES: The aim of this study was to assess and investigate the synergistic effect of hyaluronic acid (HA) and autologous platelet-rich plasma (a-PRP) injections on facial skin rejuvenation. METHODS: For this randomized controlled prospective study, 93 eligible patients were enrolled and randomized into 3 intervention groups to undergo a series of 3 treatment sessions with either a-PRP, HA, or a mixture of a-PRP and HA (Cellular Matrix; Regen Lab) injected into facial cheeks. RESULTS:A total of 93 patients were included. Treatment with Cellular Matrix led to a very significant improvement in the overall facial appearance compared with treatment with a-PRP or HA alone (P < 0.0001). Participants treated with Cellular Matrix showed a 20%, 24%, and 17% increase in FACE-Q score at 1, 3, and 6 months posttreatment, respectively. For the HA group, the improvement in FACE-Q score was 12%, 11%, and 6% at 1, 3, and 6 months posttreatment, respectively, whereas for the a-PRP group the improvement was 9%, 11%, and 8% at 1, 3, and 6 months posttreatment, respectively. Biophysical measurements showed significantly improved skin elasticity for the Cellular Matrix group compared with the groups receiving a-PRP or HA alone. No serious adverse events were reported. CONCLUSIONS: Combining a-PRP and HA seems to be a promising treatment for facial rejuvenation with a highly significant improvement in facial appearance and skin elasticity compared with a-PRP or HA alone.
RCT Entities:
BACKGROUND: Many therapeutic options are currently available for facial skin rejuvenation, but little evidence exists about the efficacy of combining such procedures. OBJECTIVES: The aim of this study was to assess and investigate the synergistic effect of hyaluronic acid (HA) and autologous platelet-rich plasma (a-PRP) injections on facial skin rejuvenation. METHODS: For this randomized controlled prospective study, 93 eligible patients were enrolled and randomized into 3 intervention groups to undergo a series of 3 treatment sessions with either a-PRP, HA, or a mixture of a-PRP and HA (Cellular Matrix; Regen Lab) injected into facial cheeks. RESULTS: A total of 93 patients were included. Treatment with Cellular Matrix led to a very significant improvement in the overall facial appearance compared with treatment with a-PRP or HA alone (P < 0.0001). Participants treated with Cellular Matrix showed a 20%, 24%, and 17% increase in FACE-Q score at 1, 3, and 6 months posttreatment, respectively. For the HA group, the improvement in FACE-Q score was 12%, 11%, and 6% at 1, 3, and 6 months posttreatment, respectively, whereas for the a-PRP group the improvement was 9%, 11%, and 8% at 1, 3, and 6 months posttreatment, respectively. Biophysical measurements showed significantly improved skin elasticity for the Cellular Matrix group compared with the groups receiving a-PRP or HA alone. No serious adverse events were reported. CONCLUSIONS: Combining a-PRP and HA seems to be a promising treatment for facial rejuvenation with a highly significant improvement in facial appearance and skin elasticity compared with a-PRP or HA alone.
Authors: Sophie K Hasiba-Pappas; Alexandru Cristian Tuca; Hanna Luze; Sebastian P Nischwitz; Robert Zrim; Judith C J Geißler; David Benjamin Lumenta; Lars-P Kamolz; Raimund Winter Journal: Transfus Med Hemother Date: 2022-05-02 Impact factor: 4.040
Authors: Simone La Padula; Rosita Pensato; Francesco D'Andrea; Ludovica de Gregorio; Concetta Errico; Umberto Rega; Luigi Canta; Chiara Pizza; Giovanni Roccaro; Raphaelle Billon; Endri Dibra; Jean Paul Meningaud; Barbara Hersant Journal: J Clin Med Date: 2022-06-16 Impact factor: 4.964
Authors: Zhouxiao Li; Thilo Ludwig Schenck; Riccardo Enzo Giunta; Lucas Etzel; Konstantin Christoph Koban Journal: J Clin Med Date: 2022-07-11 Impact factor: 4.964
Authors: Simone La Padula; Rosita Pensato; Chiara Pizza; Edoardo Coiante; Giovanni Roccaro; Benedetto Longo; Francesco D'Andrea; Francesco Saverio Wirz; Barbara Hersant; Jean Paul Meningaud Journal: J Clin Med Date: 2022-09-28 Impact factor: 4.964